クロミフェン。クエン酸クロミフェン
English Journal
- Dietary beta-cryptoxanthin inhibits N-butyl-N-(4-hydroxybutyl)nitrosamine-induced urinary bladder carcinogenesis in male ICR mice.
- Miyazawa K, Miyamoto S, Suzuki R, Yasui Y, Ikeda R, Kohno H, Yano M, Tanaka T, Hata K, Suzuki K.Author information Department of Urogenital Surgery, Kanazawa Medical University, Ishikawa 920-0293, Japan.AbstractRecent epidemiological studies have indicated that high dietary consumption of fruit and vegetables results in lower risk of bladder cancer. To confirm these findings, we investigated in the current study the effects of dietary administration with beta-cryptoxanthin extracted from Citras unshiu oranges on N-butyl-N-(4-hydroxybutyl)nitrosamine (OH-BBN)-induced urinary bladder carcinogenesis in mice. Male ICR mice were divided into 6 experimental and control groups. Groups 1 through 4 were given OH-BBN (500 ppm) in drinking water for 6 weeks to induced urinary bladder neoplasms. Mice in groups 2, 3 and 4 were fed the diets mixed with 1, 5 and 25 ppm of beta-cryptoxanthin, respectively, starting 1 week after the cessation of OH-BBN exposure, and kept on these diets for 24 weeks until the termination of the study. Group 5 was treated with the diet containing the test compound (25 ppm) alone, and group 6 served as an untreated control. All animals were sacrificed at week 32 for histopathology and immunohistochemistry (cyclin D1). Feeding with beta-cryptoxanthin decreased the incidence and multiplicity of preneoplastic and neoplastic lesions of urinary bladder. Notably, the highest dose (25 ppm) of the test chemical significantly lowered the occurrence of bladder carcinoma, in conjunction with reducing the cyclin D1-positive cell ratio. These findings suggest that beta-cryptoxanthin is able to prevent OH-BBN-induced bladder carcinogenesis in mice.
- Oncology reports.Oncol Rep.2007 Feb;17(2):297-304.
- Recent epidemiological studies have indicated that high dietary consumption of fruit and vegetables results in lower risk of bladder cancer. To confirm these findings, we investigated in the current study the effects of dietary administration with beta-cryptoxanthin extracted from Citras unshiu oran
- PMID 17203164
- Central haemodynamics during induction of neurolept anaesthesia in patients with arteriosclerotic heart disease.
- Bille-Brahe NE, Sorensen MB, Mondorf T, Engell HC.AbstractThe haemodynamic changes occurring during induction of neurolept anaesthesia and intubation in patients with reduced cardiac reserve were compared with the haemodynamic changes observed prior to operation during the stress of moderate physical exercise in the same patients. Anaesthesia consisted of droperidolum NFN (Dehydrobenzperidol), fentanyli citras NFN (Haldid) and nitrous oxide-oxygen with suxamethonium for intubation. The haemodynamic parameters measured were mean arterial blood pressure, central venous pressure, pulmonary artery mean pressure, pulmonary capillary wedge pressure and cardiac output. Blood volume was also measured, as were arterial blood-gas tensions and pH. The haemodynamic changes observed during induction with intubation were significantly smaller than those observed preoperatively during exercise.
- Acta anaesthesiologica Scandinavica. Supplementum.Acta Anaesthesiol Scand Suppl.1978;67:47-54.
- The haemodynamic changes occurring during induction of neurolept anaesthesia and intubation in patients with reduced cardiac reserve were compared with the haemodynamic changes observed prior to operation during the stress of moderate physical exercise in the same patients. Anaesthesia consisted of
- PMID 278455
Related Links
- Monographs: Pharmaceutical substances: Clomifene citrate (Clomifeni citras) Molecular formula. C 26 H 28 ClNO,C 6 H 8 O 7 Relative molecular mass. 598.1 Graphic formula. Chemical name. 2-[p-(2-Chloro-1,2-diphenylvinylN,N ...
- Zobacz ulotkę leku Clostilbegyt (Clomifeni citras). Sprawdź skład, zastosowanie, dawkowanie i opis preparatu w Encyklopedii leków portalu Dbam o Zdrowie. ... Encyklopedia leków dostarczy Ci wyczerpujących ...
★リンクテーブル★
[★]
- 英
- clomiphene, clomifene
- 化
- クエン酸クロミフェン クロミフェンクエン酸塩 clomifene citrate clomifeni citras
- 同
- クロラミフェン chloramiphene
- 商
- クロミッド、セロフェン、スパクロミン
- 関
- エンクロミフェン、エストロゲン。クロミフェン療法
作用機序
- 弱いエストロゲン作用と中程度の抗エストロゲン作用を有しており、視床下部のエストロゲン受容体に競合的に結合して(ネガティブフィードバックを解除することで？。単なる競合阻害薬として作用するのであろう)、ゴナドトロピン放出ホルモン、ゴナドトロピンの分泌を促す。
- ⇔ GnRHアゴニスト(GnRH受容体アゴニスト。下垂体のGnRH受容体のダウンレギュレーションを狙って用いられる。これによりゴナドトロピンの分泌が抑制される。)
薬理作用
適応
排卵誘発
- 投与方法：月経第5日から5日間
- 排卵率：70-80%
- 1-5の卵胞が成熟卵胞となる ⇔ hMG刺激では数個から十数個の卵胞が成熟卵胞となる。
禁忌
重要な基本的注意
- 参考1
- (1) 投与前少なくとも1ヵ月間及び治療期間中は基礎体温を必ず記録させ，排卵誘発の有無を観察すること。
- (2) 無月経患者においては投与前にgestagen testを行い，消退性出血開始日を第1日として5日目に，また投与前に自然出血（無排卵周期症）があった場合はその5日目に投与を開始すること。
- (3) 投与後基礎体温が高温相に移行した場合は，投与を中止し，必ず妊娠成立の有無を確認すること。
副作用
- 頚管粘液低下、子宮内膜発育不良(抗エストロゲン作用に基づく)
- 参考1
- 卵巣過剰刺激(≧5%。下腹部痛等の卵巣腫大症状)、虚血性視神経症(≧5%)、霧視等の視覚症状(＞0.1-5%未満)、過敏症(≧5%。発疹等)、精神変調(≧5%)、頭痛・情動不安等(0.1-5％未満)、肝臓酵素異常(≧5%。AST上昇,ALT上昇,ビリルビン上昇,γ-GTP上昇)、肝機能低下(＜0.1%。5%以上のBSP排泄遅延)、悪心・嘔吐・食欲不振等(＜0.1-5%)、顔面潮紅・尿量増加・口渇・疲労感(＜0.1-5%)
臨床関連
参考
- http://www.info.pmda.go.jp/go/pack/2499009F1080_1_03/2499009F1080_1_03